NASDAQ: NTRB - Nutriband Inc.

Yield per half year: -30.85%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Nutriband Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd.

more details
for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-11-30
ISIN US67092M2089
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://nutriband.com
Цена ао 6.61
Change price per day: -1.01% (4.96)
Change price per week: -1.21% (4.97)
Change price per month: -25.27% (6.57)
Change price per 3 month: +15.8% (4.24)
Change price per half year: -30.85% (7.1)
Change price per year: +14.99% (4.27)
Change price per 3 year: -5.39% (5.19)
Change price per 5 year: -50.9% (10)
Change price per year to date: +20.34% (4.08)
All parameters

Underestimation

Title Value Grade
P/S 10.39 1
P/BV 3.37 5
P/E 0 0
EV/EBITDA -4.18 0
Total: 4.13

Efficiency

Title Value Grade
ROA, % -64.63 0
ROE, % -73.08 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0471 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 462.08 10
Yield Ebitda, % 169.57 10
Yield EPS, % 28.33 4
Total: 8.4
More

Institutions Volume Share, %
Vanguard Group Inc 85224 1.09
Geode Capital Management, LLC 58571 0.75
State Street Corporation 17266 0.22
Alphaq Advisors LLC 11668 0.15
Atria Wealth Solutions, Inc. 10934 0.14
Osaic Holdings Inc 7585 0.1
Tower Research Capital LLC (TRC) 3078 0.04
UBS Group AG 800 0.01
Royal Bank of Canada 86 0
Wells Fargo & Company 36 0



Head Job title Payment Year of birth
Mr. Serguei Melnik Founder, President, Company Secretary & Executive Chairman of the Board 175k 1974 (51 year)
Mr. Gareth Sheridan Founder, CEO & Director 175k 1990 (35 years)
Mr. Gerald Goodman CFO & Chief Accounting Officer 140k 1948 (77 years)
Dr. Alan Smith Ph.D. COO & President of 4P Therapeutics 159k 1966 (59 years)
Dr. Jeffrey Patrick Pharm.D. Chief Scientific Officer N/A 1970 (55 years)
Mr. Tyler Overk Head of Active Intelligence N/A 1984 (41 year)
Mr. Michael Myer President of Pocono Pharmaceutical 40.6k 1985 (40 years)

Address: United States, Orlando. FL, 121 South Orange Avenue - open in Google maps, open in Yandex maps
Website: https://nutriband.com